<?xml version="1.0" encoding="UTF-8"?>
<p id="Par56">A potential subject who meets the following criterion will be excluded from participation in this study: 
 <list list-type="bullet">
  <list-item>
   <p id="Par57">concomitant systemic therapies with other anti-cancer agents, e.g. BRAF-inhibitor, anti-CTLA4 (e.g. ipilimumab), or other PD-1 blockade than nivolumab or pembrolizumab</p>
  </list-item>
 </list>
</p>
